# Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.

> **NCT00945282** · PHASE2 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 8 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus

## Interventions

- **DRUG:** GSK2248761
- **DRUG:** Lopinavir/ritonavir
- **DRUG:** HAART
- **DRUG:** Placebo
- **DRUG:** GSK2248761

## Key facts

- **NCT ID:** NCT00945282
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-20
- **Primary completion:** 2009-11-28
- **Final completion:** 2009-11-28
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2018-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00945282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00945282, "Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00945282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*